An observational study in Pelvic Toxicity, Radiation Toxicity and Chemotherapy Toxicity, sponsored by Bernardino Clavo, MD, PhD. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Bernardino Clavo, MD, PhD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
328 studies on the registry are indexed under Radiation Injuries; 96 are open to participants now.
This study's planned enrollment of 38 is below the median of 130 across 96 observational studies indexed under Radiation Injuries.
Browse Radiation Injuries studies →Bernardino Clavo, MD, PhD is the lead sponsor of 10 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with gynecological tumors treated with RT and/or CT with or without chronic pelvic toxicity (TPIRQT).
Inclusion Criteria for all patients (Cases and Controls):
Must accept and sign the specific for this study.
Additional Inclusion Criteria for inclusion in the TPIRQT Group (Cases):
Exclusion Criteria for all patients (Cases and Controls):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with gynecological tumors treated with RT and/or CT who develop chronic pelvic toxicity (TPIRQT) and are referred for compassionate-use rectal ozone therapy at the Chronic Pain Unit. Samples and data will be collected before and after ozone therapy
pelvic toxicity (TPIRQT). This group will be matched by age (± 5 years) and primary tumor location. Samples and data will be collected once during a follow-up visit.
Comparison of gut microbiome profile (composition and diversity) between TPIRQT and Control groups
Gut microbiome composition and diversity (from a single sample) in control patients will be compared to the baseline profile of patients with TPIRQT.
Time frame: Baseline (single time point for controls, pre-ozone for cases)
Change in gut microbiome profile (composition and diversity) in patients with TPIRQT after rectal ozone therapy.
Gut microbiome composition and diversity will be analyzed from stool samples using 16S ribosomal RNA gene sequencing.
Time frame: Baseline (pre-ozone therapy) , 4 Months (post-ozone therapy)
Correlation of gut microbiome profile with grade of pelvic toxicity.
Toxicity will be assessed using: i) the CTCAE v.5.0 scale from the NCI , and ii) the EORTC QLQ-CX24 questionnaire. This will be evaluated for its relationship to microbiome data.
Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
Correlation of gut microbiome profile with health-related quality of life (HRQoL).
HRQoL will be assessed using: i) the EQ-5D-5L questionnaire, and ii) the EORTC QLQ-C30 questionnaire. This will be evaluated for its relationship to microbiome data.
Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
Correlation of gut microbiome profile with anxiety and depression levels.
Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). This will be evaluated for its relationship to microbiome data.
Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
Correlation of gut microbiome profile with biochemical markers of oxidative stress and inflammation.
Serum samples will be collected to analyze biochemical parameters of oxidative stress and inflammation and their potential relationship with gut microbiome composition.
Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
Plan to share: Yes — It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification Data will be available after publication, ending 36 months following article publication. They will be available for investigators whose proposed use of the data has been apd by an independent review committee identified for this purpose.
Time frame: Data will be available after publication, ending 36 months following article publication.
Access criteria: They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose
Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.
Of 55 observational studies under Radiation Injuries, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 189. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bernardino Clavo, MD, PhD